Tirzepatide and retatrutide are often mentioned in the same breath as the next step beyond single-target GLP-1 drugs like semaglutide, and both are covered in their own dedicated guides elsewhere on this site. They share a family resemblance, both are multi-receptor "agonist" peptides designed to activate more than one metabolic hormone pathway at once, but they differ in mechanism, regulatory status, and how much we actually know about them, and those differences matter more than the headline weight-loss percentages that usually get compared.
Mechanism: Dual vs. Triple Agonist
Tirzepatide is a dual agonist, activating both the GLP-1 receptor and the GIP receptor. It's the active ingredient in Zepbound (for weight management) and Mounjaro (for type 2 diabetes), both FDA-approved. Retatrutide goes a step further as a triple agonist, activating GLP-1, GIP, and glucagon receptors. The added glucagon activity is the theoretical basis for retatrutide's larger reported weight-loss numbers, since glucagon receptor activation is associated with increased energy expenditure and fat metabolism on top of the appetite-suppressing effects both drugs share through GLP-1 and GIP.
Regulatory Status: Approved vs. Investigational
This is the most important practical difference between the two. Tirzepatide is FDA-approved and has been available by prescription for years. Retatrutide is not FDA-approved for any use and remains in Phase 3 clinical trials as part of Eli Lilly's TRIUMPH program; the only way to legitimately receive retatrutide right now is as a participant in one of those ongoing trials. Any retatrutide sold outside a clinical trial is an unapproved, unregulated product, not a legitimate version of the investigational drug being studied.
Comparing the Numbers, Carefully
Tirzepatide's pivotal SURMOUNT-1 trial reported average weight loss of roughly 21% at the highest studied dose over 72 weeks in adults with obesity. Retatrutide's first Phase 3 trial, TRIUMPH-1, reported average weight loss of up to roughly 30% at the highest dose, as covered in this site's article on that trial. It's tempting to read those two numbers side by side and conclude retatrutide simply outperforms tirzepatide, but that comparison has a real limitation: these are two separate trials, run with different specific patient populations, not a single head-to-head study randomizing the same population to one drug or the other. No completed head-to-head randomized trial between retatrutide and tirzepatide has been published. Cross-trial comparisons like this one are commonly used as an early signal in drug development, but they consistently overstate or understate real differences compared with a proper head-to-head trial, which is the only way to know with confidence how the two would actually compare in the same patients.
Side Effects
Both drugs share the gastrointestinal side effects common to this entire drug class, including nausea, vomiting, diarrhea, and constipation, particularly during dose escalation. Retatrutide's added glucagon receptor activity has raised a specific question researchers are watching closely in its trials: glucagon signaling can increase heart rate, so retatrutide's cardiovascular safety profile, including any effect on heart rate, is something its ongoing and future trials will need to characterize fully before any approval decision, in a way that's already well established for tirzepatide.
The Bottom Line
If you're choosing a treatment today, that choice is really between tirzepatide and other already-approved options, since retatrutide isn't available outside clinical trials. Retatrutide's early trial results are a legitimately promising signal for where this drug class may be headed, but "promising Phase 3 data" and "an approved medication with years of post-market safety data" are different things, and it will take completed trials, an FDA review, and time on the market for retatrutide to reach the evidence standard tirzepatide already meets. Anyone weighing these options, including whether to join a retatrutide trial, should do so in conversation with a doctor familiar with their full medical history.